Table 2. Univariate and multivariate analysis for PSA recurrence-free survival in 167 PCa patients.
|
Recurrence-free survival |
|||
|---|---|---|---|
| |
Univariate |
Multivariate |
|
| Characteristic | P-value | HR (95%CI) | P-value |
| Age (years) | 0.525 | ||
| <65 | |||
| ≧65 |
|
|
|
| PSA |
<0.001 |
|
|
| <15 | |||
| ≧15 |
|
|
|
| Gleason score |
0.073 |
|
|
| ≦6 | |||
| ≧7 |
|
|
|
| Pathological T stage |
<0.001 |
|
<0.001 |
| ≦pT2 | |||
| ≧pT3 |
|
4.667 (2.358-9.234) |
|
| MVD |
<0.001 |
|
|
| <120 per mm2 | |||
| ≧120 per mm2 |
|
|
|
| VASH1 density |
<0.001 |
|
0.007 |
| <12 per mm2 | |||
| ≧12 per mm2 | 2.950 (1.349–6.449) | ||
Abbreviations: CI=confidence interval; HR=hazard ratio; MVD=microvessel density; PCa=prostate cancer; PSA=prostate-specific antigen; VASH1=vasohibin-1.